Limited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by McDougle, C. J.
	Articles by Price, L. H.
	Search for Related Content



	PubMed Citation
	Articles by McDougle, C. J.
	Articles by Price, L. H.

Am J Psychiatry 1993; 150:647-649
Copyright © 1993 by American Psychiatric Association

BRIEF REPORTS

Limited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder

CJ McDougle, WK Goodman, JF Leckman, JC Holzer, LC Barr, E McCance-Katz, GR Heninger and LH Price
Clinical Neuroscience Research Unit, Yale University School of Medicine, Connecticut Mental Health Center, New Haven 06519.

The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better than placebo in reducing obsessive-compulsive, depressive, or anxiety symptoms. This finding suggests that addition of buspirone to ongoing fluvoxamine therapy is not an effective treatment strategy for most patients with obsessive- compulsive disorder.

This article has been cited by other articles:

K. J Craig and N. A Fineberg
OCD and anxiety: from afterthought to independence
J Psychopharmacol, March 1, 2008; 22(2): 217 - 219.
[PDF]

J. H. Greist and J. W. Jefferson
Obsessive-Compulsive Disorder
Focus, January 1, 2007; 5(3): 283 - 298.
[Abstract] [Full Text] [PDF]

N. A. Fineberg, T. M. Gale, and T. Sivakumaran
A review of antipsychotics in the treatment of obsessive compulsive disorder
J Psychopharmacol, January 1, 2006; 20(1): 97 - 103.
[PDF]

A. Kaplan and E. Hollander
A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Focus, July 1, 2004; 2(3): 454 - 461.
[Abstract] [Full Text] [PDF]

A. Kaplan and E. Hollander
A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Psychiatr Serv, August 1, 2003; 54(8): 1111 - 1118.
[Abstract] [Full Text] [PDF]

R. Ramasubbu, C. J. McDougle, and L. H. Price
Antiobsessional Effect of Risperidone Add-On Treatment in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder May Be Dose-Dependent
Arch Gen Psychiatry, May 1, 2002; 59(5): 472 - 473.
[Full Text] [PDF]

C. J. McDougle, C. N. Epperson, G. H. Pelton, S. Wasylink, and L. H. Price
A Double-blind, Placebo-Controlled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-compulsive Disorder
Arch Gen Psychiatry, August 1, 2000; 57(8): 794 - 801.
[Abstract] [Full Text] [PDF]

J. h. Greist, J. W. Jefferson, K. A. Kobak, D. J. Katzelnick, and R. C. Serlin
Efficacy and Tolerability of Serotonin Transport Inhibitors in Obsessive-compulsive Disorder: A Meta-analysis
Arch Gen Psychiatry, January 1, 1995; 52(1): 53 - 60.
[Abstract] [PDF]

C. J. McDougle, W. K. Goodman, J. F. Leckman, N. C. Lee, G. R. Heninger, and L. H. Price
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics
Arch Gen Psychiatry, April 1, 1994; 51(4): 302 - 308.
[Abstract] [PDF]

Get information about faster international access.